Extended-release minocycline dosage forms
US8722650B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2010 |
| Grant date | May 13, 2014 |
| Priority date | — |
| Expiry date | Aug 28, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/65
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.